PMC:7600245 / 70563-71491 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T306","span":{"begin":410,"end":415},"obj":"Body_part"}],"attributes":[{"id":"A306","pred":"fma_id","subj":"T306","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Mechanistically, it has both micro-biostatic and micro-biocidal effects depending on its concentration. The former effect happens at low concentrations due to the binding of this cationic molecule to the negatively charged extracellular components of some microbes, which causes an alteration of osmotic equilibrium and leakage of essential ions. At higher concentrations, the molecule gets into the microbial cells and precipitates intracellular components, leading to microbial death [252,253,254,255]. Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48). Recently, computational methods have proposed chlorhexidine to be an inhibitor of 3CLpro and/or RdRp of SARS-CoV-2 [169], yet this potential is to be experimentally demonstrated."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T334","span":{"begin":718,"end":726},"obj":"Disease"},{"id":"T335","span":{"begin":854,"end":862},"obj":"Disease"}],"attributes":[{"id":"A334","pred":"mondo_id","subj":"T334","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A335","pred":"mondo_id","subj":"T335","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Mechanistically, it has both micro-biostatic and micro-biocidal effects depending on its concentration. The former effect happens at low concentrations due to the binding of this cationic molecule to the negatively charged extracellular components of some microbes, which causes an alteration of osmotic equilibrium and leakage of essential ions. At higher concentrations, the molecule gets into the microbial cells and precipitates intracellular components, leading to microbial death [252,253,254,255]. Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48). Recently, computational methods have proposed chlorhexidine to be an inhibitor of 3CLpro and/or RdRp of SARS-CoV-2 [169], yet this potential is to be experimentally demonstrated."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T726","span":{"begin":20,"end":23},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T727","span":{"begin":410,"end":415},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T728","span":{"begin":562,"end":568},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T729","span":{"begin":572,"end":573},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T730","span":{"begin":591,"end":596},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T731","span":{"begin":745,"end":747},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"}],"text":"Mechanistically, it has both micro-biostatic and micro-biocidal effects depending on its concentration. The former effect happens at low concentrations due to the binding of this cationic molecule to the negatively charged extracellular components of some microbes, which causes an alteration of osmotic equilibrium and leakage of essential ions. At higher concentrations, the molecule gets into the microbial cells and precipitates intracellular components, leading to microbial death [252,253,254,255]. Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48). Recently, computational methods have proposed chlorhexidine to be an inhibitor of 3CLpro and/or RdRp of SARS-CoV-2 [169], yet this potential is to be experimentally demonstrated."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T84856","span":{"begin":188,"end":196},"obj":"Chemical"},{"id":"T94572","span":{"begin":341,"end":345},"obj":"Chemical"},{"id":"T28738","span":{"begin":377,"end":385},"obj":"Chemical"},{"id":"T77845","span":{"begin":522,"end":535},"obj":"Chemical"},{"id":"T84072","span":{"begin":591,"end":596},"obj":"Chemical"},{"id":"T3791","span":{"begin":665,"end":668},"obj":"Chemical"},{"id":"T49188","span":{"begin":796,"end":809},"obj":"Chemical"},{"id":"T264","span":{"begin":819,"end":828},"obj":"Chemical"}],"attributes":[{"id":"A39194","pred":"chebi_id","subj":"T84856","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A40382","pred":"chebi_id","subj":"T94572","obj":"http://purl.obolibrary.org/obo/CHEBI_24870"},{"id":"A13629","pred":"chebi_id","subj":"T28738","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A98901","pred":"chebi_id","subj":"T77845","obj":"http://purl.obolibrary.org/obo/CHEBI_3614"},{"id":"A94345","pred":"chebi_id","subj":"T84072","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A33582","pred":"chebi_id","subj":"T3791","obj":"http://purl.obolibrary.org/obo/CHEBI_29287"},{"id":"A6595","pred":"chebi_id","subj":"T49188","obj":"http://purl.obolibrary.org/obo/CHEBI_3614"},{"id":"A42195","pred":"chebi_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Mechanistically, it has both micro-biostatic and micro-biocidal effects depending on its concentration. The former effect happens at low concentrations due to the binding of this cationic molecule to the negatively charged extracellular components of some microbes, which causes an alteration of osmotic equilibrium and leakage of essential ions. At higher concentrations, the molecule gets into the microbial cells and precipitates intracellular components, leading to microbial death [252,253,254,255]. Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48). Recently, computational methods have proposed chlorhexidine to be an inhibitor of 3CLpro and/or RdRp of SARS-CoV-2 [169], yet this potential is to be experimentally demonstrated."}

{"project":"LitCovid-sentences","denotations":[{"id":"T551","span":{"begin":0,"end":103},"obj":"Sentence"},{"id":"T552","span":{"begin":104,"end":346},"obj":"Sentence"},{"id":"T553","span":{"begin":347,"end":504},"obj":"Sentence"},{"id":"T554","span":{"begin":505,"end":749},"obj":"Sentence"},{"id":"T555","span":{"begin":750,"end":928},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mechanistically, it has both micro-biostatic and micro-biocidal effects depending on its concentration. The former effect happens at low concentrations due to the binding of this cationic molecule to the negatively charged extracellular components of some microbes, which causes an alteration of osmotic equilibrium and leakage of essential ions. At higher concentrations, the molecule gets into the microbial cells and precipitates intracellular components, leading to microbial death [252,253,254,255]. Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48). Recently, computational methods have proposed chlorhexidine to be an inhibitor of 3CLpro and/or RdRp of SARS-CoV-2 [169], yet this potential is to be experimentally demonstrated."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2197","span":{"begin":846,"end":850},"obj":"Gene"},{"id":"2198","span":{"begin":704,"end":712},"obj":"Species"},{"id":"2199","span":{"begin":854,"end":864},"obj":"Species"},{"id":"2200","span":{"begin":522,"end":535},"obj":"Chemical"},{"id":"2201","span":{"begin":796,"end":809},"obj":"Chemical"},{"id":"2202","span":{"begin":480,"end":485},"obj":"Disease"},{"id":"2203","span":{"begin":718,"end":726},"obj":"Disease"}],"attributes":[{"id":"A2197","pred":"tao:has_database_id","subj":"2197","obj":"Gene:43740578"},{"id":"A2198","pred":"tao:has_database_id","subj":"2198","obj":"Tax:9606"},{"id":"A2199","pred":"tao:has_database_id","subj":"2199","obj":"Tax:2697049"},{"id":"A2200","pred":"tao:has_database_id","subj":"2200","obj":"MESH:D002710"},{"id":"A2201","pred":"tao:has_database_id","subj":"2201","obj":"MESH:D002710"},{"id":"A2202","pred":"tao:has_database_id","subj":"2202","obj":"MESH:D003643"},{"id":"A2203","pred":"tao:has_database_id","subj":"2203","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Mechanistically, it has both micro-biostatic and micro-biocidal effects depending on its concentration. The former effect happens at low concentrations due to the binding of this cationic molecule to the negatively charged extracellular components of some microbes, which causes an alteration of osmotic equilibrium and leakage of essential ions. At higher concentrations, the molecule gets into the microbial cells and precipitates intracellular components, leading to microbial death [252,253,254,255]. Currently, 0.12% chlorhexidine oral/nasal rinse is being tested in a randomized, open-label, single-institution study so as to evaluate its potential to reduce oro- and naso-pharyngeal viral load in patients with COVID-19 (NCT04344236; n = 48). Recently, computational methods have proposed chlorhexidine to be an inhibitor of 3CLpro and/or RdRp of SARS-CoV-2 [169], yet this potential is to be experimentally demonstrated."}